Wehale.Life
Patient support
Product info
Insights
Events
Patient benefits
Patients
Healthcare professionals
- Contact us
- Country Ireland
  - - Choose language
    - Choose country
      
      Global
      
      Belgium
      
      Czech Republic
      
      Denmark
      
      Finland
      
      Germany
      
      Hungary
      
      Ireland
      
      Netherlands
      
      Poland
      
      Spain
      
      Sweden
      
      Ukraine
      
      United Kingdom
- Policies

Healthcare Professionals (IE)
Insights

Insights

Date of preparation: Jan 2021 / EASYH-1052(3)

Insights: Register to access this content

Insights

Carbon Footprint of Bufomix (budesonide / formoterol) Easyhaler<sup>®</sup> reduced by 12.1% between 2019 and 2023

Carbon Footprint of Bufomix (budesonide / formoterol) Easyhaler^® reduced by 12.1% between 2019 and 2023

Insights

Global strategy for the diagnosis, management, and prevention of COPD — What has changed in GOLD 2023?

Global strategy for the diagnosis, management, and prevention of COPD — What has changed in GOLD 2023?

Insights

Managing COPD correctly leads to less exacerbations and better quality of life

Managing COPD correctly leads to less exacerbations and better quality of life

Insights

Inadequate prescription, poor adherence, and errors in inhaler technique contribute to poor asthma control

Inadequate prescription, poor adherence, and errors in inhaler technique contribute to poor asthma control

Insights

Clinical effectiveness of Budesonide/Formoterol Fumarate Easyhaler<sup>® </sup> for patients with poorly controlled obstructive airway disease: a real-world study of patient-reported outcomes

Clinical effectiveness of Budesonide/Formoterol Fumarate Easyhaler^® for patients with poorly controlled obstructive airway disease: a real-world study of patient-reported outcomes

Insights

Switching to <br>Bufomix (budesonide/formoterol) Easyhaler<sup>® </sup> may improve disease control and health related quality of life

Switching to
Bufomix (budesonide/formoterol) Easyhaler^® may improve disease control and health related quality of life

Insights

Patients with asthma or COPD are able to efficiently use Easyhaler<sup>®</sup> regardless of age or disease severity

Patients with asthma or COPD are able to efficiently use Easyhaler^® regardless of age or disease severity

Insights

Dry powder inhalers – how to minimise handling errors and ensure patient satisfaction

Dry powder inhalers – how to minimise handling errors and ensure patient satisfaction

Insights

Global Initiative for Asthma — What is new in GINA 2022?

Global Initiative for Asthma — What is new in GINA 2022?

Insights

Ability of patients with asthma to achieve correct inspiratory flow rates for different inhalers

Ability of patients with asthma to achieve correct inspiratory flow rates for different inhalers

Insights

Assessing patient inspiratory flow rate for clinical efficacy with<br> Bufomix (Budesonide/Formoterol) Easyhaler<sup>®</sup>

Assessing patient inspiratory flow rate for clinical efficacy with
Bufomix (Budesonide/Formoterol) Easyhaler^®

Insights

Evaluation of the efficiency of single-inhaler combination therapy with budesonide/formoterol fumarate in patients with bronchial asthma in daily clinical practice

Evaluation of the efficiency of single-inhaler combination therapy with budesonide/formoterol fumarate in patients with bronchial asthma in daily clinical practice

Insights

Global Initiative for Asthma: Updates in the 2021 GINA Report

Global Initiative for Asthma: Updates in the 2021 GINA Report

Insights

Switching to the Easyhaler Device to control Asthma and COPD: A literature review

Switching to the Easyhaler Device to control Asthma and COPD: A literature review

Insights

Science says singing is good for COPD patients – 3 positive ways to relieve COPD symptoms

Science says singing is good for COPD patients – 3 positive ways to relieve COPD symptoms

Insights

The importance of patient satisfaction, preference, and adherence to inhaler for long-term asthma control

The importance of patient satisfaction, preference, and adherence to inhaler for long-term asthma control

Insights

Bufomix (budesonide/formoterol) Easyhaler<sup>® </sup> Maintenance and Reliever Therapy: MART

Bufomix (budesonide/formoterol) Easyhaler^® Maintenance and Reliever Therapy: MART

Insights

More asthma patients achieve the optimal inspiratory flow for high-resistance inhalers than for low-resistance inhalers

More asthma patients achieve the optimal inspiratory flow for high-resistance inhalers than for low-resistance inhalers

Insights

Easy, convenient, and environmentally friendly asthma and COPD care with Easyhaler®

Easy, convenient, and environmentally friendly asthma and COPD care with Easyhaler®

Insights

Comprehensive asthma care with Bufomix (budesonide/formoterol) Easyhaler<sup>®</sup> maintenance and reliever therapy (MART)

Comprehensive asthma care with Bufomix (budesonide/formoterol) Easyhaler^® maintenance and reliever therapy (MART)

Insights

Inhaler technical features and patient education in supporting successful treatment of asthma and COPD

Inhaler technical features and patient education in supporting successful treatment of asthma and COPD

Read more

PATIENT SUPPORT
PRODUCT INFO
INSIGHTS

DATE OF PREPARATION: MAY 2023/EASYH-688(10)

FULL PRESCRIBING INFORMATION AVAILABLE HERE

For more information about Orion and Sustainability click here

Adverse effects should be reported. You can report side effects directly via the Health Products Regulatory Authority (HPRA) website: www.hpra.ie or by email on medsafety@hpra.ie. Adverse effects should also be reported to Orion Pharma via ie.medicalinformation@orionpharma.com

OrionPharma

Orion Pharma Ireland Ltd.
C/o Allphar Services, 4045 Kingswood Rd, Citywest Business Pk, D24V06K
Tel: General Enquiries & Customer Care +353 1 428 7777 /
Medical Information +353 1 468 8482 or
Email ie.medicalinformation@orionpharma.com
Date of Preparation: July 2024 / EASYH-638(9)

Policies Contact us © Copyright Orion Corporation

This information is intended for healthcare professionals in Ireland. This site contains promotional information. By clicking "Yes" you are confirming that you are a HCP and you will enter the HCP site. Click "No" to be taken to the public site.